About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

132.81 -0.25 (-0.18%)
Streaming Delayed Price Updated: 11:40 AM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 897,810
Open 133.77
Bid (Size) 132.76 (200)
Ask (Size) 132.85 (200)
Prev. Close 133.05
Today's Range 132.69 - 134.65
52wk Range 97.86 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.47%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference ↗
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing... 
Via MarketBeat
News headline image
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and d... 
Via StockStory
Topics Earnings

Performance

YTD
+9.2%
+9.2%
1 Month
-4.5%
-4.5%
3 Month
-14.8%
-14.8%
6 Month
+7.6%
+7.6%
1 Year
+30.9%
+30.9%

More News

Read More
News headline image
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead (GILD) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance ↗
Via Chartmill
These S&P500 stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
Via StockStory
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue
Via StockStory
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability ↗
Via Chartmill
News headline image
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy ↗
Via Investor's Business Daily
News headline image
Gilead Sciences Announces First Quarter Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Likely To Report Higher Q1 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
Via Benzinga
News headline image
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings To Watch: Gilead Sciences (GILD) Reports Q1 Results Tomorrow
Via StockStory
Topics Artificial Intelligence
News headline image
Tempus AI (TEM) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
1 S&P 500 Stock to Own for Decades and 2 We Avoid
Via StockStory
Topics Stocks
News headline image
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
Via StockStory
News headline image
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?
Via Barchart.com
Topics ETFs
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
Via Benzinga
News headline image
Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks That Pay You While You Wait for the Growth ↗
Via The Motley Fool
Topics Intellectual Property

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 132.81
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 05/14/26 11:40 AM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 166.51B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 167B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.